ConductScience.org, home

Paper42579041

Association of implementation of secondary fracture prevention incentives after hip fracture and risk of subsequent fracture in real-world practice.

Hiyama Y and 1 other. Eur Geriatr Med, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Association of implementation of secondary fracture prevention incentives after hip fracture and risk of subsequent fracture in real-world practice. Papers, record 42579041. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42579041

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Association of implementation of secondary fracture prevention incentives after hip fracture and risk of subsequent fracture in real-world practice.
PubMed
Journal
Eur Geriatr Med
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-11
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hiyama YYoshinorihttps://orcid.org/0000-0002-8388-7182
2Ohtera SShosukehttps://orcid.org/0000-0002-8873-3676

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References40

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136374576What was the Epidemiology and Global Burden of Disease of Hip Fractures From 1990 to 2019? Results From and Additional Analysis of the Global Burden of Disease Study 2019.Clin Orthop Relat Res2023https://conductscience.org/library/papers/36374576PubMed
237118993Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post-Fracture Treatment, and All-Cause Mortality.J Bone Miner Res2023https://conductscience.org/library/papers/37118993PubMed
335364728Incidence of different types of subsequent fractures and related mortality in Taiwan.Arch Osteoporos2022https://conductscience.org/library/papers/35364728PubMed
430864015Short-term risk factors for a second hip fracture in a UK population.Eur J Orthop Surg Traumatol2019https://conductscience.org/library/papers/30864015PubMed
535441744Incidence of Subsequent Hip Fracture and Mortality in Elderly Patients: A Multistate Population-Based Cohort Study in Eastern Spain.J Bone Miner Res2022https://conductscience.org/library/papers/35441744PubMed
632659601The impact of second hip fracture on rehospitalization and mortality in older adults.Arch Gerontol Geriatr2020https://conductscience.org/library/papers/32659601PubMed
738536447Effectiveness of fracture liaison service in reducing the risk of secondary fragility fractures in adults aged 50 and older: a systematic review and meta-analysis.Osteoporos Int2024https://conductscience.org/library/papers/38536447PubMed
833829285The impact of fracture liaison services on subsequent fractures and mortality: a systematic literature review and meta-analysis.Osteoporos Int2021https://conductscience.org/library/papers/33829285PubMed
933522384Physical Therapy Management of Older Adults With Hip Fracture.J Orthop Sports Phys Ther2021https://conductscience.org/library/papers/33522384PubMed
1038952014Zoledronic acid for hip fracture during initial hospitalization.J Bone Miner Res2024https://conductscience.org/library/papers/38952014PubMed
1139808195Fracture liaison service (FLS) is associated with lower subsequent fragility fracture risk and mortality: NoFRACT (the Norwegian capture the fracture initiative).Osteoporos Int2025https://conductscience.org/library/papers/39808195PubMed
1236205166Anti-osteoporotic treatment after hip fracture remains alarmingly low.Dan Med J2022https://conductscience.org/library/papers/36205166PubMed
1330646034Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis.JAMA Netw Open2018https://conductscience.org/library/papers/30646034PubMed
1440592642Current status of patients with hip fracture in Japan: A nationwide survey.J Orthop Sci2026https://conductscience.org/library/papers/40592642PubMed
1541091162Impact of a national reimbursement policy on anti-osteoporosis medication prescription at discharge after hip-fracture surgery in Japan: an interrupted time-series analysis.Osteoporos Int2025https://conductscience.org/library/papers/41091162PubMed
1639671048
Impact of the guidance on fracture Liaison Services and the introduction of a new fee for secondary fracture prevention in Japan: Implementation of secondary fracture prevention during hospitalization for fragility fractures.
Osteoporos Int2025https://conductscience.org/library/papers/39671048PubMed
1740226165DeSC database.Ann Clin Epidemiol2025https://conductscience.org/library/papers/40226165PubMed
1820234789Hip fracture incidence in Japan: estimates of new patients in 2007 and 20-year trends.Arch Osteoporos2009https://conductscience.org/library/papers/20234789PubMed
1940938461Temporal trends in acute care costs of hip fracture treatment from 2011 to 2021 in Japan.Arch Osteoporos2025https://conductscience.org/library/papers/40938461PubMed
2038988134Following hip fracture, hospital organizational factors associated with prescription of anti-osteoporosis medication on discharge, to address imminent refracture risk: a record-linkage study.J Bone Miner Res2024https://conductscience.org/library/papers/38988134PubMed

See all 40 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42579041

GET https://conductscience.org/api/papers/v1/42579041/references?page=2